Novartis AG's 177Lu-PSMA-617 has met both overall survival (OS) and radiographic progression-free survival (PFS) primary endpoints in the Phase III VISION study in prostate cancer, but the company is holding back, for now, on the extent of the therapeutic benefit of the candidate radiotherapy.
The Basel, Switzerland-based big pharma released the top-line results of the VISION study on 23 March, and said it would present further details of the targeted radioligand’s significant improvement of OS and PFS in advanced prostate cancer at an upcoming medical meeting
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?